Fibroblast growth factor 21.
Development
Endocrine
Fibroblast growth factor
Hormone
Immunity
Metabolism
Journal
Differentiation; research in biological diversity
ISSN: 1432-0436
Titre abrégé: Differentiation
Pays: England
ID NLM: 0401650
Informations de publication
Date de publication:
29 Jun 2024
29 Jun 2024
Historique:
received:
01
09
2023
revised:
23
06
2024
accepted:
28
06
2024
medline:
12
7
2024
pubmed:
12
7
2024
entrez:
11
7
2024
Statut:
aheadofprint
Résumé
Fibroblast growth factor 21 (FGF21) belongs to the FGF19 subfamily and acts systemically, playing a key role in inter-organ crosstalk. Ranging from metabolism, reproduction, and immunity, FGF21 is a pleiotropic hormone which contributes to various physiological processes. Although most of its production across species stems from hepatic tissues, expression of FGF21 in mice has also been identified in adipose tissue, thymus, heart, pancreas, and skeletal muscle. Elevated FGF21 levels are affiliated with various diseases and conditions, such as obesity, type 2 diabetes, preeclampsia, as well as cancer. Murine knockout models are viable and show modest weight gain, while overexpression and gain-of-function models display resistance to weight gain, altered bone volume, and enhanced immunity. In addition, FGF21-based therapies are at the forefront of biopharmaceutical strategies aimed at treating metabolic dysfunction-associated steatotic liver disease.
Identifiants
pubmed: 38991938
pii: S0301-4681(24)00049-5
doi: 10.1016/j.diff.2024.100793
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
100793Informations de copyright
Copyright © 2024 International Society of Differentiation. Published by Elsevier B.V. All rights reserved.